• InflaRx management commentary reported a EUR 18.68 million nine-month net loss through September 30, 2026, versus EUR 34.99 million a year earlier.
• Research and development expenses fell to EUR 11.94 million, reflecting lower external-service costs, reduced share-based compensation and prior-year program wind-down provisions.
• Sales and marketing expenses declined by EUR 3.37 million, primarily reflecting the discontinuation of active GOHIBIC sales activities in December 2025.
• Operating cash outflows narrowed to EUR 14 million from EUR 30.61 million a year earlier.
• Available funds totaled EUR 153.3 million, bolstered by EUR 119.3 million in net proceeds from the May 2026 ordinary-share offering.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inflarx NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-26-041698), on November 03, 2026, and is solely responsible for the information contained therein.